MLTX logo

MOONLAKE IMMUNOTHERAPEUTICS

MLTXNASDAQ
🏆 #2464 by market capUS Equity
$310.25▲ $14.86 (+4.79%)
Simulated price
🔔
Track MLTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.01B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for MLTX.

Trading Snapshot

Day Range
$308.27 – $311.74
52-Week Range
$5.95 – $23.29
Volume
$1.57B
Avg Volume
$1.78B
Shares Outstanding
84.1M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$166M
Last Q Revenue
$39M
P/E Ratio
-3.1
P/S Ratio
0.0x
EPS (TTM)
$-3.57
Dividend Yield
0.00%
Dilution (1yr)
+2.2%

Why Investors Own MLTX

  • ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 41% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MLTX logo

MOONLAKE IMMUNOTHERAPEUTICS

MLTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$245M▲ +71.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$196M▲ +67.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.5M▲ +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$259M▲ +$81M YoY
StockOtter · stockotter.space

About MOONLAKE IMMUNOTHERAPEUTICS

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$403.44
▲ +30.0% Upside
High Target$501.04
Low Target$347.24
Based on 21 analysts

Latest News & Updates

🚀
Reuters·2h ago

MOONLAKE IMMUNOTHERAPEUTICS tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift MLTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

MOONLAKE IMMUNOTHERAPEUTICS announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.